Subject Index
Coagulation Factors and Inhibitors
Fibrinolysis, fibrinogen, fibrin
Haemorrhagic Disorders
Invited
Other
Platelets
Thrombotic Disorders and antithrombotic therapy
Vascular Biology
Thrombotic Disorders and antithrombotic therapy
Animal and experimental models
Antiphospholipid antibodies
Cancer and thrombosis
Cerebrovascular disease
Clinical trials: antiplatelet agents
Clinical trials: direct antithrombin agents
Clinical trials: fibrinolytic therapy
Clinical trials: heparins/LMWH
Clinical trials: oral anticoagulants
Diabetes and metabolic disorders
DVT and pulmonary embolism
Familial thrombosis
Gene therapy
Genetic determinants and epidemiology
Homocysteine
Hormone, pregnancy
Hypercoagulability
Inflammation, infection and immunity
Ischaemic heart disease
New antithrombotic agents and approaches
New intravascular devices
Other thrombotic disorders and antithrombotic therapy
Polymorphism and arterial disease
TTP and HUS
A comparative pharmacodynamic study of anti-Xa activity to evaluate the accumulation effect of Tinzaparin and Enoxaparin given at prophylactic dose over 8 days in elderly patients with impaired renal function
Aghasaryan M., Mazoyer E., Mahé I., dit Bal Sollier C., Simoneau G., Berge N., Soulat T., Bergmann J. - F., Heilmann J.-J., Drouet L., Caulin C.
A comparison between routine plasma INRs and fingerstick whole blood INRs determinations, using three portable self-testing devices (Coagucheck®, Pro-Time®, Gem-PLC®) and a near-patient whole blood device (Thrombotrack®)
De Monte P., Filippucci E., Boschetti E., Trottini S., Cavalieri G., Gresele P.
A dose-finding study of Tinzaparin in pediatric patients
Kuhle S., Massicotte M. P., Dinyari M., Andrew M., Chan A. K. C., Mitchell D., Vegh P., Mitchell L.
A novel recombinant tissue factor assay for measuring the anti-Xa effect of Low-Molecular-Weight Heparin (LMWH): implications for interventional coronary procedures
Laduca F., Lee T., El Rouby S., Zucker M., Cohen M.
A pharmacokinetic study of tinzaparin in pediatric patients
Kuhle S., Massicotte M. P., Dinyari M., Marzinotto V., Mitchell D., Pieniaszek H., Andrew M., Chan A. K. C., Vegh P., Mitchell L.
A program for the point of care testing (POCT) of the ACT to ensure safe control of heparinization in coronary angioplasty
Creagh M. D., Carson P. J., Johnstone T., Loar P.
A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus study
Agnelli G., Bergqvist D., Cohen A., Gallus A., Gent M.
A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely Ill medical patients: the PREVENT medical thromboprophylaxis study
Leizorovicz A., Cohen A. T., Turpie A. G. G., Olsson C. G., Vaitkus P. T., Goldhaber S. Z.
A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by Warfarin Sodium
Hull R. D., Pineo G. F., Mah A. F., Brant R. F. for the LITE Investigators
Activation of blood coagulation in patients undergoing perioperative blood salvage and reinfusion of no-washed whole blood after total knee arthroplasty
Filippucci E., Biagini D., Pagliaricci S., Agnelli G.
Autophosphorylation of focal adhesion kinase at Tyr397 in collagen-stimulated human platelets
Marcinkiewicz M., Gear A.R.L., Polanowska-Grabowska R.K.
Bridging therapy for mechanical heart valves: a model comparing unfractionated and low molecular weight heparin
Garcia D., Rich J. S., Libby E.
Combined analysis of 2 studies on the clinical outcome over 6 months in patients with symptomatic acute deep vein thrombosis initially treated with one low-molecular-weight heparin
Harenberg J., Bueller H., Huismann M., Riess H., Brom J., Weidinger G.
Different thromboprophylaxis approaches in patients undergoing knee arthroscopy (KANT study): interim report of prospective randomized study
Camporese G., N'Tita K., Rossi F., Bernardi E., Verlato F., Salmistraro G., Cordova R., Franz F., Hartmann L., Simioni P., Prandoni P., Andreozzi G. M.
Differential diagnostics of abnormal uterine bleeding
Makatsaria A. D., Saidova R. A.
Does rebound exist? A comparison of venous thromboembolic event rates in the post-treatment period for patients randomized to long-term low-molecular-weight heparin vs. warfarin sodium
Pineo G. F., Hull R. D., Mah A. F., Lite Investigators†
Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study
Hull R., Schellong S., Tapson V., Yusen R., Monreal M., Samama M. M., Turpie A. G. G., Wildgoose P., Cort S.
Factors that influence the prescribing of low-molecular-weight heparins (LMWHs) in community hospitals: opinions of physicians, clinical pharmacists, and formulary committee members
Nutescu E. A., Park H. Y., Walton S. M., Lewis R. K., Finely J. M., Blackburn J. C., Schumock G. T.
Improving bridge-out therapy with low-molecular-weight heparin in an urban, inner city medical center
Dumo P., Racine E., Popovic B., Gortney J.
Induction of serum hepatocyte growth factor/activin/follistatin system during enoxaparin-anti-coagulated hemodialysis
Borawski J., Naumnik B., Mysliwiec M.
Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE)
Lee A. Y. Y., Levine M. N., Baker R. I., Bowden C., Kakkar A. K., Prins M., Rickles F. R., Julian J. A., Haley S., Kovacs M. J., Gent M.
Low molecular heparin in prophylaxis of thrombohamorragic complications after caesarean delivery in patients with cardiologic deseases
Makatsaria A., Babessa R. F., Marov S. V.
Low molecular weight heparin therapy in neonatal cerebral sinovenous thrombosis: a consecutive cohort study
Deveber G., Chan A. K., Shroff M., Macgregor D. L., Massicotte M. P., Curtis R. M., Adams M. M.
Low molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anti-coagulants
Iorio A., Guercini F., Conti S., Pini M.
Low-molecular-weight heparin dose requirements are age-related through childhood
Manco-Johnson M., Graham D., Valentino L., Knapp-Clevenger R.
Non-invasive detection of proximal DVT using bilateral compression ultrasound: methodology for the EXCLAIM study
Schellong S., Hull R., Tapson V., Yusen R., Monreal M., Samama M. M., Turpie A. G. G., Cort S., Wildgoose P.
Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement
Hull R. D., Kakkar A. K., Marder V. J., Pineo G. F., Goldberg M. M., Raskob G. E., for the PROTECT Trial Investigators¶
Perioperative management of patients on oral anti-coagulants: a decision-analysis
Dunn A., Ho W., Wisnivesky J., Moore C., Mcginn T., Sacks H. S.
Phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis
Breddin H., Kadziola Z., Scully M., Nakov R., Misselwitz F., Kakkar V. V.
Prolongation of the aPTT is far inferior to thrombin generation as an indicator of the heparin anti-coagulant effect
Hemker H. C.
Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery
Kolb G., Bodamer I., Galster H., Grambach K., Koudela K., Eisele R. R., Becker C., Paal V., Spannagel U., Brom J., Weidinger G.
Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) after major abdominal surgery: the FAME study
Rasmussen M. S., Jorgensen L. N., Wille-Jørgensen P., Nielsen J. D., Soemod L., Harvald T., Horn A., Mohn A. C., Pilsgaard B., Olsen B.
Prolonged thromboprophylaxis with low molecular weight heparin (tinzaparin) following major general surgery primarily for cancer: An individual patient data meta-analysis
Jorgensen L. N., Lausen I., Rasmussen M. S., Wille-Jorgensen P., Bergqvist D., Prism Trial Investigators
Prophylaxis of deep vein thrombosis after lower extremity amputation: comparison of low molecular weight heparin with unfractionated heparin
Lastoria S., Rollo H. A., Giannini M., Moura R., Yoshida W. B., Maffei F. H. A.
Relation between circulating endothelial markers and anti-coagulation with different heparins in hemodialysis patients: a prospective study
Naumnik B., Borawski J., Mysliwiec M.
Relation of changes in D-dimer and other coagulation markers with changes in Marder Score after treatment of acute venous thrombosis with the low molecular weight heparin Certoparin or unfractionated heparin
Harenberg J., Merx K., Tolle A. R., Huisman M. V.
Safety and efficacy of nadroparin for the treatment or prophylaxis of venous thromboembolism in pregnancy
Barillari G., Springolo F., Santuz M., Biffoni F.
Subcutaneous adjusted-dose unfractionated heparin vs. fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism
Prandoni P., Carnovali M., Marchiori A., Ghirarduzzi A., Girolami B., Quintavalla R., Tropeano P. F., Alatri A., Accorsi F., Todini A. R., Moia M., Scannapieco G. L., Villalta S., Cogo A., Imberti D., Parente F., Agnelli G., Sartori D., Cuppini S., Migliacci R., Corà F., Bagatella P., Girolami A.
The impact of intravenous heparin administration on duration of hospitalization
Dunn A., Capasso M., Beran M., Bioh D., Siu A.
Thromboprophylaxis in laparoscopic cholecystectomy: identification of a high-risk group of patients
Volteas S., Sikiotis K.
Treatment of acute pulmonary embolism during pregnancy with low-molecular weight heparin
Kaaja R., Ulander V.- M.
Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy
Kaaja R., Ulander V.-M.
Unfractionated heparin, but not a low-molecular-weight heparin (Clivarin), mediates differential generation of anti-heparin-PF4 antibodies in orthopedic surgery patients: Pathophysiologic and pharmacologic implications
Ahmad S., Haas S., Bacher P., Misselwitz F., Reid U., Hoppensteadt D. A., Fareed J.